Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 21, 2007

Presidio Reneges on Part of $75.25M HIV Drug Agreement with Medivir

  • Presidio Pharmaceuticals elected to return the license rights to Medivir’s HIV nucleoside reverse transcriptase inhibitor, MIV-310. This enables Medivir to transfer the license to Beijing Mefuvir Medicinal Technology, a subsidiary of Tianjin Human-Care Latex, a Chinese condom manufacturer.

    The amendment to this year-old agreement between Presidio and Medivir will result in a $20 million reduction in the original $75.25 million deal. Inked in December 2006, Presidio gained licenses to Phase II MIV-310 and MIV-410 a preclinical compound. The new transaction will now allow for $52.25 million based on milestones related to the development of MIV-410.


    Under the new agreement for MIV-310, Mefuvir will finance the clinical development in pursuit of registration in Asia where it has obtained the marketing rights  with the exception of Japan.

    “MIV-310 has, in Phase II trials, shown remarkable potency against multidrug-resistant HIV,” says Bo Öberg, CEO, Medivir HIV Franchise. “In laboratory experiments the combination of MIV-310 and AZT shows synergistic effects against HIV and at the same time antagonistic toxicity.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »